Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glibenclamide - Remedy Pharmaceuticals

Next Previous
Drug Profile

Glibenclamide - Remedy Pharmaceuticals

Alternative Names: BIIB 093; CIRARA; Diabeta; Glybenclamide; Glyburide for injection; RP-1127

Latest Information Update: 01 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Remedy Pharmaceuticals
  • Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas; Vascular disorder therapies
  • Mechanism of Action ABCC8 protein antagonists; TRPM4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Subarachnoid haemorrhage; Stroke
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stroke
  • Phase II Brain injuries
  • Discontinued Spinal cord injuries

Most Recent Events

  • 18 Mar 2025 Remedy Pharmaceuticals receives two additional patent allowance for CIRARA™ (IV glyburide) in the USA
  • 19 Nov 2024 Remedy Pharmaceuticals plans a phase III confirmatory trial for Stroke in USA (IV)
  • 22 Oct 2024 Glibenclamide - Remedy Pharmaceuticals receives Orphan Drug status for Stroke in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top